Similarly, ATOR-1015 increases the intratumoral CD8+ Teff/Treg ratio by depleting Tregs and increasing the infiltration/expansion and cytotoxic activity of Teffs without affecting systemic T cells.Treatment with ATOR-1015 reduces tumor growth and prolongs survival in several tumor models. This evidence concerns the gene CD8A and neoplasm.